Monica M. Jablonski, Ph.D.

Monica M. Jablonski, Ph.D.

Professor
Department of Ophthalmology
Department of Anatomy and Neurobiology


The University of Tennessee Health Science Center
Hamilton Eye Institute
930 Madison Avenue, Suite 710
Memphis, TN 38163
Phone: (901) 448-7572
Fax: (901) 448-5028
Email: Monica M. Jablonski



Education

  • Ph.D. Institution: Medical College of Wisconsin, Department of Physiology
  • Postdoctoral: Baylor College of Medicine, Department of Ophthalmology

Link

Research Interests

Mechanisms that regulate photoreceptor outer segment assembly; mouse models of eye disease; proteomics; retinal cell biology; mutagenesis; genetics modulators of glaucoma

Representative Publications

  • Janga KY, Tatke A, Shukla S, Lamichhane SP, Avula B, Wang X, Jablonski MM, Khan IA, Majumdar S. Retina compatible interactions and effective modulation of blood ocular barrier P-gp activity by third-generation inhibitors improves ocular penetration of loperamide. J Pharm Sci. 2018 Apr 17. pii: S0022-3549(18)30211-9. doi: 10.1016/j.xphs.2018.04.008. [Epub ahead of print] PubMed PMID: 29678592.
  • Tatke A, Janga KY, Avula B, Wang X, Jablonski MM, Khan IA, Majumdar S. P-glycoprotein Restricts Ocular Penetration of Loperamide across the Blood-Ocular Barriers: a Comparative Study in Mdr1a Knock-out and Wild Type Sprague Dawley Rats. AAPS PharmSciTech. 2018 Mar 8. doi: 10.1208/s12249-018-0979-2. [Epub ahead of print] PubMed PMID: 29520587.
  • Janga KY, Tatke A, Balguri SP, Lamichanne SP, Ibrahim MM, Maria DN, Jablonski MM, Majumdar S. Ion-sensitive in situ hydrogels of natamycin bilosomes for enhanced and prolonged ocular pharmacotherapy: in vitro permeability, cytotoxicity and in vivo evaluation. Artif Cells Nanomed Biotechnol. 2018 Feb 23:1-12. doi: 10.1080/21691401.2018.1443117. [Epub ahead of print] PubMed PMID: 29475386.
  • Chintalapudi SR, Maria D, Di Wang X, Bailey JNC; NEIGHBORHOOD consortium; International Glaucoma Genetics consortium, Hysi PG, Wiggs JL, Williams RW, Jablonski MM. Systems genetics identifies a role for Cacna2d1 regulation in elevated intraocular pressure and glaucoma susceptibility. Nat Commun. 2017 Nov 24;8(1):1755. doi: 10.1038/s41467-017-00837-5. PubMed PMID: 29176626; PubMed Central PMCID: PMC5701146.
  • Cui J, Sun D, Lu H, Dai R, Xing L, Dong H, Wang L, Wei D, Jiang B, Jiao Y, Jablonski MM, Charles S, Gu W, Chen H. Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study. Eye (Lond). 2018 Feb;32(2):391-399. doi: 10.1038/eye.2017.187. Epub 2017 Sep 22. PubMed PMID: 28937147; PubMed Central PMCID: PMC5805597.
  • Li H, Chintalapudi SR, Jablonski MM. Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development. Expert Opin Investig Drugs. 2017 Oct;26(10):1103-1114. doi: 10.1080/13543784.2017.1369042. Epub 2017 Aug 24. Review. PubMed PMID: 28816076.

View more references (pubmed link)